Vascular endothelial growth factor A inhibitors - Pipeline Insight, 2022
Description
“Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Understanding
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Overview
The VEGF (vascular endothelial growth factor) pathway has emerged as an important target for cancer therapy, with VEGF signaling pathway (VSP) inhibitors having been approved for several different malignancies. The human VEGF family consists of 5 related glycoproteins: VEGFA, VEGFB, VEGFC, VEGFD, and PIGF (placental growth factor). These are secreted to form homodimers, which interact with a family of 3 receptor tyrosine kinases: VEGFR1 (VEGF receptor 1), VEGFR2, and VEGFR3. VEGFA and VEGFB bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and VEGFD bind to both VEGFR2 and VEGFR3.
VSP inhibitors have been found to reduce NO pathway metabolites and NO-dependent processes. Inhibition of VEGF pathway is a strategy being widely pursued to provide new therapeutics for the treatment of VEGF related disorders.
Novel antiangiogenic cancer therapies, particularly agents that block vascular endothelial growth factor (VEGF) signalling, have improved outcomes in patients with cancers and are now used as first-line therapies for some tumours. However, with VEGF inhibitors (VEGFIs) are new complications, particularly hypertension. VEGFI-induced hypertension is a dose-dependent phenomenon due to on-target effects rather than off-target effects.
Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor R&D. The therapies under development are focused on novel approaches for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs Chapters
This segment of the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs
• SOK583A1: Sandoz
Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea).
It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz, a division of Novartis.
• VK-2809: Viking Therapeutics
VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH.
It is currently in Phase II stage of development and is being developed by Viking Therapeutics.
Further product details are provided in the report……..
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor
There are approx. 40+ key companies which are developing the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor. The companies which have their Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Sandoz.
• Phases
DelveInsight’s report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Insights
• Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
• How many companies are developing Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs?
• How many Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Sandoz
• Sam Chun Dang Pharm
• Samsung Bioepis
• Luye Pharma
• Shanghai Henlius Biotech
• Generium Pharmaceuticals
• Bioeq GmbH
• Roche
• Chong Kun Dang Pharmaceutical
• Outlook Therapeutics
• Qilu Pharmaceuticals
• AngioLab
• Sinocelltech
• Alteogen
• Adverum Biotechnologies
• Boehringer Ingelheim
• Eyevensys
• Oxford BioMedica
Key Products
• SOK583A1
• SCD411
• SB15
• LY09004
• HLX04-O
• GNR-067
• Faricimab
• FYB203
• CKD-701
• ONS-5010
• BCD 300
• ALS-L1023
• SCT510A
• ALT-L9
• ADVM-022
• BI 836880
• EYS609
• OXB-203
Geography Covered
• Global coverage
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Understanding
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Overview
The VEGF (vascular endothelial growth factor) pathway has emerged as an important target for cancer therapy, with VEGF signaling pathway (VSP) inhibitors having been approved for several different malignancies. The human VEGF family consists of 5 related glycoproteins: VEGFA, VEGFB, VEGFC, VEGFD, and PIGF (placental growth factor). These are secreted to form homodimers, which interact with a family of 3 receptor tyrosine kinases: VEGFR1 (VEGF receptor 1), VEGFR2, and VEGFR3. VEGFA and VEGFB bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and VEGFD bind to both VEGFR2 and VEGFR3.
VSP inhibitors have been found to reduce NO pathway metabolites and NO-dependent processes. Inhibition of VEGF pathway is a strategy being widely pursued to provide new therapeutics for the treatment of VEGF related disorders.
Novel antiangiogenic cancer therapies, particularly agents that block vascular endothelial growth factor (VEGF) signalling, have improved outcomes in patients with cancers and are now used as first-line therapies for some tumours. However, with VEGF inhibitors (VEGFIs) are new complications, particularly hypertension. VEGFI-induced hypertension is a dose-dependent phenomenon due to on-target effects rather than off-target effects.
Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor R&D. The therapies under development are focused on novel approaches for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs Chapters
This segment of the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs
• SOK583A1: Sandoz
Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea).
It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz, a division of Novartis.
• VK-2809: Viking Therapeutics
VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH.
It is currently in Phase II stage of development and is being developed by Viking Therapeutics.
Further product details are provided in the report……..
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor
There are approx. 40+ key companies which are developing the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor. The companies which have their Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Sandoz.
• Phases
DelveInsight’s report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs.
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Insights
• Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
• How many companies are developing Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs?
• How many Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Sandoz
• Sam Chun Dang Pharm
• Samsung Bioepis
• Luye Pharma
• Shanghai Henlius Biotech
• Generium Pharmaceuticals
• Bioeq GmbH
• Roche
• Chong Kun Dang Pharmaceutical
• Outlook Therapeutics
• Qilu Pharmaceuticals
• AngioLab
• Sinocelltech
• Alteogen
• Adverum Biotechnologies
• Boehringer Ingelheim
• Eyevensys
• Oxford BioMedica
Key Products
• SOK583A1
• SCD411
• SB15
• LY09004
• HLX04-O
• GNR-067
• Faricimab
• FYB203
• CKD-701
• ONS-5010
• BCD 300
• ALS-L1023
• SCT510A
• ALT-L9
• ADVM-022
• BI 836880
• EYS609
• OXB-203
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor : Overview
- • Structure
- • Mechanism of Action
- Pipeline Therapeutics
- • Comparative Analysis
- Therapeutic Assessment
- • Assessment by Product Type
- • Assessment by Stage and Product Type
- • Assessment by Route of Administration
- • Assessment by Stage and Route of Administration
- • Assessment by Molecule Type
- • Assessment by Stage and Molecule Type
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- • Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Collaboration Deals
- • Company-Company Collaborations (Licensing / Partnering) Analysis
- • Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- • Comparative Analysis
- SOK583A1: Sandoz
- • Product Description
- • Research and Development
- • Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- • Comparative Analysis
- ALS-L1023: AngioLab
- • Product Description
- • Research and Development
- • Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- • Comparative Analysis
- ALT-L9: Alteogen
- • Product Description
- • Research and Development
- • Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- • Comparative Analysis
- EYS609: Eyevensys
- • Product Description
- • Research and Development
- • Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- • Comparative Analysis
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Companies
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Products
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Unmet Needs
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Market Drivers and Barriers
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Future Perspectives and Conclusion
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Analyst Views
- Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Companies
- Appendix
- Table 1 Total Products for Vascular endothelial growth factor A inhibitors
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products
- Figure 1 Total Products for Vascular endothelial growth factor A inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
